Minnesota, USA.
* Corresponding Author
GSC Advanced Research and Reviews, 2026, 29(01), 265–269
Article DOI: 10.30574/gscarr.2026.29.1.0285
Received on 12 September 2026; revised on 18 October 2026; accepted on 20 October 2026
Parkinson’s disease (PD) is a progressive neurodegenerative disorder for which available treatments are primarily symptomatic. Neuroimmune changes are implicated in PD, and experimental work has reported CD23 (FcεRII) expression in glial cells and CD23-associated inflammatory mediator production in vitro. These findings provide a rationale for investigating CD23, but they do not establish that CD23 drives disease progression or that its modulation is therapeutic. This hypothesis-generating review considers whether a preformed anti-IgE antibody–IgE complex, such as UB-221 (also referred to as CUE-221), could alter CD23-associated signaling in PD. The proposed effects on glia, NOS2, and neuronal injury remain untested, as does the complex's ability to reach relevant brain compartments. Potential delivery approaches—including receptor-mediated transport and focused ultrasound—are discussed as research options rather than established solutions. Preclinical studies should first determine target expression, complex behavior and safety, functional effects in relevant PD models, and brain exposure. CD23-directed immunomodulation is therefore a speculative research hypothesis, not an established disease-modifying strategy.
Parkinson’s Disease, Neuroinflammation, Immunotherapy, CD23, Preformed CUE22: Ige, B-Cell Modulation
Preview Article PDF
Michael John Dochniak. CD23 IN PARKINSON’S DISEASE: RATIONALE AND CHALLENGES FOR EXPLORING PREFORMED ANTI-IGE:IGE COMPLEXES. GSC Advanced Research and Reviews, 2026, 29(01), 265–269. Article DOI: https://doi.org/10.30574/gscarr.2026.29.1.0285.